ALIROCUMAB REDUCES MAJOR CARDIOVASCULAR EVENTS IN INDIVIDUALS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: A POST-HOC ANALYSIS OF ODYSSEY LONG TERM

Background: Individuals with elevated low density lipoprotein cholesterol (LDL-C) and atherosclerotic cardiovascular disease (ASCVD) are at increased risk for recurrent events. We present a post-hoc analysis of the efficacy and safety of alirocumab (ALI) vs. placebo (PL) among individuals with ASCVD